BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6679
- TODAY'S CHANGE (%)-0.0121 (-1.7794%)
- Bid / Lots0.6516/ 1
- Ask / Lots0.7100/ 22
- Open / Previous Close0.6520 / 0.6800
- Day Range
- 52 Week Range
- Volume239,169
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 2086 | 0.66 |
| 09:39 ET | 350 | 0.6798 |
| 09:43 ET | 4807 | 0.6798 |
| 09:48 ET | 400 | 0.678978 |
| 09:54 ET | 501 | 0.66 |
| 09:59 ET | 100 | 0.6699 |
| 10:06 ET | 100 | 0.67 |
| 10:08 ET | 100 | 0.67 |
| 10:10 ET | 4420 | 0.6601 |
| 10:14 ET | 800 | 0.665 |
| 10:15 ET | 2579 | 0.6677 |
| 10:19 ET | 250 | 0.6754 |
| 10:26 ET | 700 | 0.6601 |
| 10:32 ET | 228 | 0.67 |
| 10:33 ET | 800 | 0.6601 |
| 10:35 ET | 17092 | 0.6601 |
| 10:42 ET | 1566 | 0.665049 |
| 10:44 ET | 2600 | 0.67 |
| 10:46 ET | 2900 | 0.67 |
| 10:48 ET | 700 | 0.669901 |
| 10:50 ET | 2900 | 0.6699 |
| 10:51 ET | 8500 | 0.6666 |
| 10:53 ET | 1400 | 0.67 |
| 10:55 ET | 8649 | 0.67 |
| 10:57 ET | 1800 | 0.6699 |
| 11:00 ET | 2500 | 0.67 |
| 11:02 ET | 400 | 0.6699 |
| 11:04 ET | 200 | 0.66505 |
| 11:13 ET | 100 | 0.67 |
| 11:18 ET | 105 | 0.6651 |
| 11:24 ET | 700 | 0.669999 |
| 11:26 ET | 700 | 0.669999 |
| 11:27 ET | 800 | 0.6699 |
| 11:29 ET | 5800 | 0.665099 |
| 11:31 ET | 1100 | 0.665149 |
| 11:33 ET | 19600 | 0.669999 |
| 11:36 ET | 2200 | 0.6699 |
| 11:38 ET | 2400 | 0.6699 |
| 11:40 ET | 300 | 0.6697 |
| 11:42 ET | 454 | 0.66185 |
| 11:44 ET | 4300 | 0.6697 |
| 11:49 ET | 2597 | 0.6697 |
| 11:51 ET | 5000 | 0.6696 |
| 11:54 ET | 6900 | 0.6696 |
| 11:56 ET | 2500 | 0.6697 |
| 11:58 ET | 100 | 0.6697 |
| 12:03 ET | 8790 | 0.66085 |
| 12:07 ET | 9079 | 0.66085 |
| 12:09 ET | 9800 | 0.669523 |
| 12:12 ET | 2600 | 0.6697 |
| 12:14 ET | 3200 | 0.6675 |
| 12:16 ET | 8200 | 0.6608 |
| 12:18 ET | 6800 | 0.6695 |
| 12:20 ET | 3400 | 0.6608 |
| 12:21 ET | 3500 | 0.6618 |
| 12:25 ET | 100 | 0.6618 |
| 12:38 ET | 100 | 0.6605 |
| 12:41 ET | 100 | 0.6521 |
| 12:48 ET | 100 | 0.669 |
| 12:50 ET | 100 | 0.6615 |
| 12:59 ET | 1600 | 0.654 |
| 01:01 ET | 152 | 0.654 |
| 01:06 ET | 640 | 0.654151 |
| 01:14 ET | 3800 | 0.654 |
| 01:15 ET | 300 | 0.663819 |
| 01:17 ET | 600 | 0.654 |
| 01:21 ET | 250 | 0.6689 |
| 01:28 ET | 200 | 0.6689 |
| 01:35 ET | 2032 | 0.6541 |
| 01:39 ET | 173 | 0.6687 |
| 01:42 ET | 100 | 0.6688 |
| 01:48 ET | 200 | 0.658 |
| 01:51 ET | 4861 | 0.654 |
| 01:53 ET | 1000 | 0.6522 |
| 01:57 ET | 100 | 0.66 |
| 02:04 ET | 4428 | 0.6521 |
| 02:08 ET | 5310 | 0.6521 |
| 02:13 ET | 300 | 0.652 |
| 02:15 ET | 429 | 0.652 |
| 02:18 ET | 700 | 0.652 |
| 02:24 ET | 895 | 0.651407 |
| 02:26 ET | 400 | 0.652 |
| 02:27 ET | 1900 | 0.652 |
| 02:29 ET | 2000 | 0.652053 |
| 02:31 ET | 7683 | 0.6521 |
| 02:33 ET | 300 | 0.6521 |
| 02:36 ET | 500 | 0.6521 |
| 02:38 ET | 6456 | 0.6663 |
| 02:40 ET | 200 | 0.6663 |
| 02:44 ET | 100 | 0.66625 |
| 02:45 ET | 100 | 0.666 |
| 02:58 ET | 100 | 0.666 |
| 03:07 ET | 100 | 0.666 |
| 03:20 ET | 1200 | 0.6686 |
| 03:21 ET | 1400 | 0.6638 |
| 03:34 ET | 260 | 0.668651 |
| 03:43 ET | 100 | 0.6687 |
| 03:48 ET | 850 | 0.6687 |
| 03:56 ET | 3400 | 0.6671 |
| 03:57 ET | 100 | 0.6679 |
Jun 3, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 12:45PM ET on Monday Jun 03, 2024 by Dow Jones
12:45PM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD), from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
DJ BioLine RX Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 10:34AM ET on Wednesday May 29, 2024 by Dow Jones
10:34AM ET on Wednesday May 29, 2024 by Dow Jones
May 28, 2024
Press Release: BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow JonesBioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates, from 7:00AM ET on Tuesday May 28, 2024 by Dow Jones
7:00AM ET on Tuesday May 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 55.9M | -0.9x | --- |
Cue Biopharma Inc | 66.2M | -1.3x | --- |
Dyadic International Inc | 60.8M | -7.6x | --- |
Lipocine Inc | 50.8M | -5.6x | --- |
LAVA Therapeutics NV | 61.5M | -2.2x | --- |
Kronos Bio Inc | 64.9M | -0.5x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $55.9M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 79.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.54 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 4.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
